In recent years, the development of targeted therapies, such as the inhibitors of B cell receptor (BCR) signaling and of B cell lymphoma 2 (Bcl-2) protein, has changed the treatment landscape of CLL [5]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.